We report that PD-1 immune checkpoint blockade combined with CCL21-DC tumor Ag vaccine eradicates tumors and has the potential to augment therapy in lung cancer patients who have low baseline tumor T cell infiltration and do not respond to PD-1 therapy. This evidence concerns the gene CCL21 and lung cancer.